CY1110915T1 - Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων - Google Patents

Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων

Info

Publication number
CY1110915T1
CY1110915T1 CY20101101030T CY101101030T CY1110915T1 CY 1110915 T1 CY1110915 T1 CY 1110915T1 CY 20101101030 T CY20101101030 T CY 20101101030T CY 101101030 T CY101101030 T CY 101101030T CY 1110915 T1 CY1110915 T1 CY 1110915T1
Authority
CY
Cyprus
Prior art keywords
pml
gene codes
androgen receptors
specific suppression
complementary
Prior art date
Application number
CY20101101030T
Other languages
English (en)
Inventor
Annick Harel-Bellan
Slimane Ait-Si-Ali
Florence Cabon-Georget
Anne Chauchereau
François DAUTRY
Luis Martinez
Original Assignee
Centre National De La Recherche Scientifique (Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique (Cnrs) filed Critical Centre National De La Recherche Scientifique (Cnrs)
Publication of CY1110915T1 publication Critical patent/CY1110915T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)

Abstract

Η εφεύρεση αφορά ένα διπλόκλωνο ολιγονουκλεοτίδιο που χαρακτηρίζεται από το ότι συνίσταται από δύο συμπληρωματικές ολιγονουκλεοτιδικές αλληλουχίες που σχηματίζουν ένα υβρίδιο που περιλαμβάνει κάθε μία από αυτές σε ένα από τα 3' ή 5' άκρα αυτής ένα έως πέντε μη-ζευγαρωμένα νουκλεοτίδια που σχηματίζουν μονόκλωνα άκρα αλληλοκαλυπτόμενα από το υβρίδιο, μία δε των εν λόγω ολιγονουκλεοτιδικών αλληλουχιών ουσιαστικά είναι συμπληρωματική μιας αλληλουχίας στόχου που ανήκει σε ένα DNA ή RNA μόριο που θα καταστέλλετε ειδικά. Η εφεύρεση επίσης αφορά την χρήση των εν λόγω ολιγονουκλεοτιδίων στις φαρμακευτικές συνθέσεις κυρίως για την θεραπευτική αγωγή καρκίνων.
CY20101101030T 2001-11-09 2010-11-17 Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων CY1110915T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0114549A FR2832154B1 (fr) 2001-11-09 2001-11-09 Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
FR0204474A FR2838442B1 (fr) 2001-11-09 2002-04-10 Sirnas inhibiteurs de l'expression de genes responsables de l'inactivation de la p53 et leur utilisation dans le traitement des cancers
EP02793219A EP1453962B1 (fr) 2001-11-09 2002-11-08 Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un recepteur aux androgenes

Publications (1)

Publication Number Publication Date
CY1110915T1 true CY1110915T1 (el) 2015-06-10

Family

ID=26213261

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101030T CY1110915T1 (el) 2001-11-09 2010-11-17 Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων

Country Status (12)

Country Link
US (2) US7371735B2 (el)
EP (3) EP3037537A1 (el)
JP (1) JP4323952B2 (el)
AT (1) ATE478143T1 (el)
AU (1) AU2002358881A1 (el)
CA (2) CA2466773C (el)
CY (1) CY1110915T1 (el)
DE (1) DE60237391D1 (el)
DK (1) DK1453962T3 (el)
FR (2) FR2832154B1 (el)
PT (1) PT1453962E (el)
WO (1) WO2003040366A2 (el)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
EP1438405A1 (de) * 2001-01-09 2004-07-21 Ribopharma AG Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
EP1445312B1 (en) * 2001-11-21 2012-12-26 Astellas Pharma Inc. Method of inhibiting gene expression
AU2003242688A1 (en) * 2002-06-20 2004-01-06 Dsm Ip Assets B.V. Inhibition of nuclear receptors
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7781575B2 (en) * 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
GB0306148D0 (en) * 2003-03-18 2003-04-23 Milner Jo Regulation of gene expression
EP1735009A4 (en) * 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc RNAI AGENTS TARGETING THE VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF)
CN101277704A (zh) 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
WO2007011819A2 (en) * 2005-07-15 2007-01-25 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
US20100286229A1 (en) * 2005-09-30 2010-11-11 Katerina Gurova Modulation of Androgen Receptor for Treatment of Prostate Cancer
CA2629564C (en) * 2005-11-15 2014-04-22 Genoid Kft. Method of detecting pathogens
US7740880B2 (en) * 2006-03-03 2010-06-22 University Of Utah Research Foundation Polymeric carrier for delivery of small interfering RNA
HUE037173T2 (hu) 2006-08-08 2018-08-28 Univ Bonn Rheinische Friedrich Wilhelms 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
AR055648A1 (es) * 2006-09-21 2007-08-29 Gen Med Sa Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
WO2009031671A1 (ja) * 2007-09-07 2009-03-12 The University Of Tokushima ｐ５３の発現促進方法およびそれに用いるｐ５３発現促進剤
DE102008014318B4 (de) * 2008-03-14 2021-02-04 Premark Feg L.L.C. Transportspülmaschine und Verfahren zum Betreiben einer Transportspülmaschine
JP5689413B2 (ja) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
CA2762524A1 (en) * 2009-05-18 2011-01-13 Ensysce Biosciences, Inc. Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
AU2011282902B2 (en) 2010-07-28 2015-01-29 Alcon Research, Ltd. siRNA targeting VEGFA and methods for treatment in vivo
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
AU2012353330B2 (en) 2011-12-16 2018-04-19 National University Corporation Tokyo Medical And Dental University Chimeric double-stranded nucleic acid
EP2867368B1 (en) 2012-07-06 2022-01-12 Institut Gustave Roussy Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
US9868952B2 (en) 2012-07-08 2018-01-16 Sirnaomics, Inc. Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
MA40782A (fr) * 2014-10-03 2017-08-08 Hocuslocus Llc Procédés et compositions utilisant un arn non codant en vue de la culture et de la sélection de cellules
CA3041630A1 (fr) * 2016-10-27 2018-05-03 Selexel Nouvel oligonucleotide double brin bisquecifiques pour le traitement des cancers
EP3755802A4 (en) * 2018-02-21 2021-11-17 Singapore Health Services Pte Ltd CANCER THERAPEUTIC TARGETING USING MUTED P53-SPECIFIC SIRNA
EP3946629A4 (en) * 2019-03-26 2023-04-05 University Of Massachusetts THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
JPH08506961A (ja) * 1993-02-19 1996-07-30 ジンタ・インコーポレイテッド アンチセンスオリゴマー類を使用するアンドロゲン関連禿頭症の治療
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
AU7983294A (en) 1993-10-19 1995-05-08 Regents Of The University Of Michigan, The P53-mediated apoptosis
US5556956A (en) * 1993-11-04 1996-09-17 Board Of Regents, The University Of Texas System Methods and compositions relating to the androgen receptor gene and uses thereof
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6150092A (en) * 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
WO1996018733A2 (en) * 1994-12-14 1996-06-20 Innovir Laboratories, Inc. Ribozyme-mediated inactivation of leukemia-associated rna
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
CN1295617A (zh) * 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
EP0978561A1 (en) 1998-08-07 2000-02-09 Hoechst Marion Roussel Deutschland GmbH Antisense oligonucleotides for the inhibition of VEGF expression
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
DE69932346T2 (de) 1998-10-26 2007-07-05 Avi Biopharma, Inc., Portland Auf Morpholin basierendes p53-Antisense- Oligonucleotid und dessen Verwendungen
IL145778A0 (en) * 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
GB9910119D0 (en) 1999-04-30 1999-06-30 Novartis Ag Organic compounds
AU5717400A (en) 1999-06-14 2001-01-02 Cancer Research Ventures Limited Cancer therapy
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
AU2925401A (en) 2000-01-19 2001-07-31 Parkash S Gill Methods and compositions for antisense vegf oligonucleotides
WO2001075164A2 (en) * 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
CA2448320A1 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Ribozyme based treatment of female reproductive diseases
US20040235171A1 (en) 2001-07-17 2004-11-25 Milner Ann Josephine Silencing of gene expression by sirna
EP1442143A4 (en) 2002-02-20 2005-02-16 Sirna Therapeutics Inc INHIBITION OF RNA INTERFERENCE-INDUCED BCL2 GENE EXPRESSION USING SMALL INTERFERING NUCLEIC ACIDS (SINA)
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
CA2501065A1 (en) 2002-09-04 2004-03-18 Johnson & Johnson Research Pty Ltd Methods using dsdna to mediate rna interference (rnai)
AU2003291678B2 (en) 2002-11-01 2009-01-15 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
EP1735009A4 (en) 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc RNAI AGENTS TARGETING THE VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF)
EP2712926A2 (en) * 2008-03-05 2014-04-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 and VEGF genes
WO2010105209A1 (en) * 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
WO2011017548A1 (en) 2009-08-05 2011-02-10 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
CN107519133A (zh) 2009-09-15 2017-12-29 阿尔尼拉姆医药品有限公司 脂质配制的组合物及抑制Eg5和VEGF基因的表达的方法

Also Published As

Publication number Publication date
FR2832154B1 (fr) 2007-03-16
FR2838442B1 (fr) 2007-06-08
EP1453962A2 (fr) 2004-09-08
EP1453962B1 (fr) 2010-08-18
PT1453962E (pt) 2010-11-29
WO2003040366A3 (fr) 2004-07-01
FR2838442A1 (fr) 2003-10-17
CA2466773A1 (fr) 2003-05-15
JP4323952B2 (ja) 2009-09-02
US20080287385A1 (en) 2008-11-20
DE60237391D1 (de) 2010-09-30
US7371735B2 (en) 2008-05-13
US8318689B2 (en) 2012-11-27
EP1939291A3 (fr) 2012-02-22
EP1939291A2 (fr) 2008-07-02
EP3037537A1 (fr) 2016-06-29
WO2003040366A2 (fr) 2003-05-15
JP2005508188A (ja) 2005-03-31
CA2466773C (fr) 2012-10-16
CA2789407A1 (fr) 2003-05-15
DK1453962T3 (da) 2010-12-20
AU2002358881A1 (en) 2003-05-19
CA2789407C (fr) 2017-10-31
ATE478143T1 (de) 2010-09-15
US20050215497A1 (en) 2005-09-29
FR2832154A1 (fr) 2003-05-16
EP1939291B1 (fr) 2016-08-17

Similar Documents

Publication Publication Date Title
CY1110915T1 (el) Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων
Arzumanov et al. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2 ‘-O-methyl/LNA oligoribonucleotides
AU660679B2 (en) Closed sense and antisense oligonucleotides and uses thereof
Fabani et al. miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide conjugates
US5989912A (en) Three component chimeric antisense oligonucleotides
US5849902A (en) Three component chimeric antisense oligonucleotides
ZA200304500B (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
IL166546A (en) Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene
JP2015523853A5 (el)
CA2385853A1 (en) Design of high affinity rnase h recruiting oligonucleotide
JP2002510207A (ja) 拡張された開裂ルールを有するハンマーヘッドリボザイム
RU2010120715A (ru) Модифицированная липидом двухцепочечная рнк, обладающая сильным эффектом рнк-интерференции
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
AU5720098A (en) G-rich oligo aptamers and methods of modulating an immune response
Arzumanov et al. Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction
Holmes et al. Steric inhibition of human immunodeficiency virus type‐1 Tat‐dependent trans‐activation in vitro and in cells by oligonucleotides containing 2′‐O‐methyl G‐clamp ribonucleoside analogues
JP2007530431A5 (el)
CA3216819A1 (en) Gene expression regulatory system using crispr system
Williamson G-quartets in biology: reprise.
JP6882735B2 (ja) 構造強化されたｍｉＲＮＡ阻害剤Ｓ−ＴｕＤ
Abe et al. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides
DE60110244D1 (de) Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide
JP2009504190A5 (el)
Yamakawa et al. Properties of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligodeoxynucleotides
AU2001258274A1 (en) Synthetic oligonucleotides as inducers of erythroid differentiation